219 related articles for article (PubMed ID: 34178093)
21. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients.
Mahmoud AM
Curr Med Res Opin; 2023 Jul; 39(7):1031-1043. PubMed ID: 37345857
[TBL] [Abstract][Full Text] [Related]
23. Bimekizumab for Moderate-to-Severe Plaque Psoriasis.
Gotesman RD; Vender R
Skin Therapy Lett; 2021 May; 26(3):1-4. PubMed ID: 34077151
[TBL] [Abstract][Full Text] [Related]
24. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
Chiricozzi A; De Simone C; Fossati B; Peris K
Psoriasis (Auckl); 2019; 9():29-35. PubMed ID: 31214486
[TBL] [Abstract][Full Text] [Related]
25. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.
Simopoulou T; Tsiogkas SG; Zafiriou E; Bogdanos DP
Drugs Today (Barc); 2023 Mar; 59(3):135-167. PubMed ID: 36847624
[TBL] [Abstract][Full Text] [Related]
26. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
Blauvelt A; Armstrong A; Merola JF; Strober B; de Cuyper D; Peterson L; Davies O; Stark JL; Lebwohl M
J Am Acad Dermatol; 2024 Jul; 91(1):72-81. PubMed ID: 38447700
[TBL] [Abstract][Full Text] [Related]
27. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.
Frieder J; Kivelevitch D; Menter A
Ther Adv Chronic Dis; 2018 Jan; 9(1):5-21. PubMed ID: 29344327
[TBL] [Abstract][Full Text] [Related]
28. The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Burshtein J; Shah M; Zakria D; Lockshin B; Crowley J; Merola JF; Gordon K; Shahriari M; Korman NJ; Chovatiya R; Kalb R; Lebwohl M
Dermatol Ther (Heidelb); 2024 Feb; 14(2):323-339. PubMed ID: 38340237
[TBL] [Abstract][Full Text] [Related]
29. Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.
Sakkas LI; Zafiriou E; Bogdanos DP
Front Pharmacol; 2019; 10():872. PubMed ID: 31447673
[TBL] [Abstract][Full Text] [Related]
30. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
[TBL] [Abstract][Full Text] [Related]
31. Bimekizumab for the treatment of psoriasis.
Thapar M; Patel M; Gordon K
Immunotherapy; 2024 Apr; 16(7):431-446. PubMed ID: 38506262
[TBL] [Abstract][Full Text] [Related]
32. Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature.
Bernardini N; Ambrosio L; Tolino E; Proietti I; Skroza N; Potenza C
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673523
[No Abstract] [Full Text] [Related]
33. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis.
Zozaya N; Abdalla F; Alfonso Zamora S; Balea Filgueiras J; Carrascosa Carrillo JM; Delgado Sánchez O; Dolz Sinisterra F; García-Ruiz A; Herranz Pinto P; Manfredi A; Martínez Olmos J; Morales de Los Ríos Luna P; Puig L; Ros S; HIdalgo-Vega Á
Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):941-953. PubMed ID: 35404728
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis.
Su QY; Yang L; Cao TY; Dang HY; Han ZC; Cao JJ; Zhang HY; Cheng T; Zhang SX; Huo YH
Expert Opin Drug Saf; 2024 Apr; ():1-9. PubMed ID: 38646719
[TBL] [Abstract][Full Text] [Related]
35. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Ritchlin CT; Kavanaugh A; Merola JF; Schett G; Scher JU; Warren RB; Gottlieb AB; Assudani D; Bedford-Rice K; Coarse J; Ink B; McInnes IB
Lancet; 2020 Feb; 395(10222):427-440. PubMed ID: 32035552
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
Chang S; Chambers CJ; Liu FT; Armstrong AW
Dermatol Online J; 2015 Jul; 21(7):. PubMed ID: 26436967
[TBL] [Abstract][Full Text] [Related]
38. Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules.
Bellinato F; Gisondi P; Girolomoni G
Biologics; 2021; 15():247-253. PubMed ID: 34239295
[TBL] [Abstract][Full Text] [Related]
39. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
40. Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Orsini D; Malagoli P; Balato A; Bianchi L; Brianti P; Buononato D; Burlando M; Caldarola G; Campanati A; Campione E; Carrera CG; Carugno A; Cusano F; Dapavo P; Dattola A; De Simone C; Dini V; Esposito M; Fargnoli MC; Gaiani FM; Gargiulo L; Gisondi P; Giunta A; Ibba L; Lasagni C; Loconsole F; Maione V; Mortato E; Marzano AV; Maurelli M; Megna M; Mercuri SR; Narcisi A; Offidani A; Paolino G; Parodi A; Pellacani G; Potestio L; Quaglino P; Richetta AG; Romano F; Sena P; Venturini M; Assorgi C; Costanzo A
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38416060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
